|
[1] D'SOUZA AA,DEVARAJAN PV. Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications[J]. J Control Release,2015,203:126-139.
|
|
[2] FRUCHART JC. Peroxisome proliferator-activated receptoralpha(PPARalpha):At the crossroads of obesity,diabetes and cardiovascular disease[J]. Atherosclerosis,2009,205(1):1-8.
|
|
[3] RAKHSHANDEHROO M,KNOCH B,MULLER M,et al. Peroxisome proliferator-activated receptor alpha target genes[J]. PPAR Res,2010,2010:pii 612089.
|
|
[4] IP E,FARRELL GC,ROBERTSON G,et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice[J]. Hepatology,2003,38(1):123-132.
|
|
[5] DONG TS,JACOBS JP. Nonalcoholic fatty liver disease and the gut microbiome:Are bacteria responsible for fatty liver?[J]. Exp Biol Med(Maywood):2019,244(6):408-418..
|
|
[6] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
|
|
[7] YANG X,FU Y,HU F,et al. PIK3R3 regulates PPARalpha expression to stimulate fatty acid beta-oxidation and decrease hepatosteatosis[J]. Exp Mol Med,2018,50(1):e431.
|
|
[8] ZHAI X,CHEN X,LU J,et al. Hydrogen-rich saline improves nonalcoholic fatty liver disease by alleviating oxidative stress and activating hepatic PPARalpha and PPARgamma[J]. Mol Med Rep,2017,15(3):1305-1312.
|
|
[9] REN T,ZHU J,ZHU L,et al. The combination of blueberry juice and probiotics ameliorate non-alcoholic steatohepatitis(NASH)by affecting SREBP-1c/PNPLA-3 pathway via PPAR-alpha[J]. Nutrients,2017,9(3):e198.
|
|
[10] CHEN J,LIU J,WANG Y,et al. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARalpha/AdipoR2,in vivo and in vitro[J]. Biomed Pharmacother,2017,91:621-631.
|
|
[11] LI TT,TAN TB,HOU HQ,et al. Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease[J]. Lipids Health Dis,2018,17(1):256-263.
|
|
[12] FRANCQUE S,VERRIJKEN A,CARON S,et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis[J]. J Hepatol,2015,63(1):164-173.
|
|
[13] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ,induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5.
|
|
[14] NANJI AA,DANNENBERG AJ,JOKELAINEN K,et al. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha(PPARalpha)-regulated genes and is ameliorated by PPARalpha activation[J]. J Pharmacol and Exp Ther,2004,310(1):417-424.
|
|
[15] FISCHER M,YOU M,MATSUMOTO M,et al. Peroxisome proliferator-activated receptor alpha(PPARalpha)agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice[J]. J Biol Chem,2003,278(30):27997-8004.
|
|
[16] LI JL,WANG QY,LUAN HY,et al. Effects of L-carnitine against oxidative stress in human hepatocytes:Involvement of peroxisome proliferator-activated receptor alpha[J]. J Biomed Sci,2012,19:32-40.
|
|
[17] NAN YM,KONG LB,REN WG,et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice[J]. Lipids Health Dis,2013,12:11-20.
|
|
[18] HUANG YC,LIU KC,CHIOU YL,et al. Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway[J].Chem Biol Interact,2013,205(3):157-164.
|
|
[19] KONG L,REN W,LI W,et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepa titis in mice[J]. Lipids Health Dis,2011,10:246.
|
|
[20] MCBRIDE G. Hepatitis B virus-induced liver cancer in Asian Americans:A preventable disease[J]. J Natl Cancer Inst,2008,100(8):528-529.
|
|
[21] DU L,MA Y,LIU M,et al. Peroxisome proliferators activated receptor(PPAR)agonists activate hepatitis B virus replication in vivo[J]. Virol J,2017,14(1):96-104.
|
|
[22] DHARANCY S,MALAPEL M,PERLEMUTER G,et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection[J]. Gastroenterology,2005,128(2):334-342.
|
|
[23] READ SA,TAY ES,SHAHIDI M,et al. The mechanism of interferon refractoriness during hepatitis C virus infection and its reversal with a peroxisome proliferator-activated receptor alpha agonist[J]. J Interferon Cytokine Res,2015,35(6):488-497.
|
|
[24] YU YC,CHEN CW. Current status and research interests of the diagnosis and treatment of cholestatic liver disease[J]. J Clin Hepatol,2019,35(2):241-246.(in Chinese)于乐成,陈成伟.胆汁淤积性肝病的诊治现状及研究方向[J].临床肝胆病杂志,2019,35(2):241-246.
|
|
[25] HUA J,NI QQ. Progress in drug treatment of cholestatic liver disease[J]. J Intern Med Concepts Pract,2018,13(6):334-338.(in Chinese)华静,倪茜茜.胆汁淤积性肝病的药物治疗进展[J].内科理论与实践,2018,13(6):334-338.
|
|
[26] ZHANG L,FAN YJ,TAN B,et al. Recognition of the clinical application and biological mechanism of ursodeoxycholic acid in liver diseases[J]. Chin J Clin Pharmacol Ther,2017,22(2):233-240.(in Chinese)张林林,樊玉娟,谭波,等.熊脱氧胆酸在慢性肝病中应用及机制的再认识[J].中国临床药理学与治疗学,2017,22(2):233-240.
|
|
[27] DAI M,YANG J,XIE M,et al. Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate[J]. Br J Pharmacol,2017,174(18):3000-3017.
|
|
[28] GHONEM NS,ASSIS DN,BOYER JL. Fibrates and cholestasis[J]. Hepatology,2015,62(2):635-643.
|
|
[29] GHONEM NS,ANANTHANARAYANAN M,SOROKA CJ,et al.Peroxisome proliferator-activated receptorαactivates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion[J]. Hepatology,2014,59(3):1030-1042.
|
|
[30] ZHU H,ZHAO YL,ZHAO QG,et al. Mechanism and clinical effect of fibrates in treatment of primary biliary cirrhosis[J].Evaluat Anal Drug-Use Hosp China,2017,17(1):10-12.(in Chinese)朱红,赵艳玲,赵庆国,等.贝特类药物治疗原发性胆汁性肝硬化的机制和疗效[J].中国医院用药评价与分析,2017,17(1):10-12.
|
|
[31] WEI XC,CHEN F,HAN XW. Acute cholestasis-type liver damage induced by fenofibrate:A case report[J]. Chin Hosp Pharm J,2019,39(3):319-320.(in Chinese)魏晓晨,陈凡,韩晓文.非诺贝特致急性胆汁淤积型肝损害1例[J].中国医院药学杂志,2019,39(3):319-320.
|
|
[32] LIU A,KRAUSZ KW,FANG ZZ,et al. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARαand its relevance to hepatotoxicity[J]. Arch Toxicol,2014,88(4):983-996.
|
|
[33] HAJDU D,AIGLOVK,VINKLEROVI,et al. Acute cholestatic hepatitis induced by fenofibrate[J]. J Clin Pharm Ther,2009,34(5):599-602.
|
|
[34] FONTANA RJ,WATKINS PB,BONKOVSKY HL,et al. Drug-induced liver injury network(DILIN)prospective study:Rationale,design and conduct[J]. Drug Saf,2009,32(1):55-68.
|
|
[35] HAQUE T,SASATOMI E,HAYASHI PH. Drug-induced liver injury:Pattern recognition and future directions[J]. Gut Liver,2016,10(1):27-36.
|
|
[36] ZHAO XQ,DONG J. Clinical features and CT imaging findings of drug-induced liver injury[J]. Chin J CT MRI,2019,17(3):83-86.(in Chinese)赵向前,董菁.药物性肝损伤患者的临床特点及CT影像学表现分析[J].中国CT和MRI杂志,2019,17(3):83-86.
|
|
[37] ZHANG Y,PAN Y,XIONG R,et al. FGF21 mediates the protective effect of fenofibrate against acetaminophen-induced hepatotoxicity via activating autophagy in mice[J]. Biochem Biophys Res Commun,2018,503(2):474-481.
|
|
[38] MINATA M,HARADA KH,KRRMAN A,et al. Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver[J]. Ind Health,2010,48(1):96-107.
|
|
[39] ZHANG Y,GUO H,HASSAN HM,et al. Pyrazinamide induced hepatic injury in rats through inhibiting the PPARαpathway[J]. J Appl Toxicol,2016,36(12):1579-1590.
|
|
[40] HEDRINGTON MS,DAVIS SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver[J].Expert Opin Drug Metab Toxicol,2018,14(7):671-677.
|
|
[41] EL-SERAG HB,RUDOLPH KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J]. Gastroenterology,2007,7(132):2557-2576.
|
|
[42] ZHAO H,ZOU LW,ZHENG SS,et al. Association between the NQO1 C609T polymorphism with hepatocellular carcinoma risk in the Chinese population[J]. Asian Pac J Cancer Prev,2015,16(5):1821-1825.
|
|
[43] LIAN X,WANG G,ZHOU H,et al. Anticancer properties of fenofibrate:A repurposing use[J]. J Cancer,2018,9(9):1527-1537.
|
|
[44] XIAO YB,CAI SH,LIU LL,et al. Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma[J]. Cancer Manag Res,2018,10:1781-1789.
|
|
[45] PINEDA TORRA I,GERVOIS P,STAELS B. Peroxisome proliferator-activated receptor alpha in metabolic disease,inflammation,atherosclerosis and aging[J]. Curr Opin Lipidol,1999,10(2):151-159.
|
|
[46] TANAKA N,MORIYA K,KIYOSAWA K,et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice[J]. J Clin Invest,2008,118(2):683-694.
|
|
[47] MASAOMI K. Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice[J]. Toxicol Pathol,2008,36(7):950-957.
|
|
[48] NISHIMURA J,DEWA Y,OKAMURA T,et al. Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats[J]. Arch Toxicol,2008,82(9):641-654.
|
DownLoad: